Dow Dips Over 500 Points; Nasdaq Down 2.5%
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 2.5% on Tuesday.
S&P 500 Down Over 1%; Crude Oil Falls Sharply
U.S. stocks traded lower midway through trading, with the Dow Jones dropping around 250 points on Tuesday.
Summit Therapeutics Shares Surge After Licensing Agreement For Cancer Program
Akeso Inc announced a collaboration and license agreement with Summit Therapeutics Inc (NASDAQ:SMMT) to out-license its breakthrough bispecific antibody, ivonescimab (PD-1/VEGF, AK112) for…
Summit Therapeutics Partners With Akeso Inc. In Deal For Up To $5B To In-License Breakthrough Innovative Bispecific Antibody
Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced a definitive agreement of its partnership with Akeso Inc. (HKEX Code: 9926.HK, "Akeso"),
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's session, 107 stocks hit new 52-week lows.
12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers
Nuwellis (NASDAQ:NUWE) stock rose 13.9% to $0.28 during Thursday's after-market session. The company's market cap stands at $8.9 million.
Summit Therapeutics Presents Ri-CoDIFy Trial Results For Microbiome-Sparing Ridinilazole At IDWeek 2022
Ridinilazole resulted in a 53% relative risk reduction in recurrence of C. difficile infection compared to treatment with vancomycin
Ridinilazole preserved the gut microbiome compared to vancomycin:
Summit Therapeutics Seeks Partnership For Phase 3 Infection Candidate Development
In an SEC filing, Summit Therapeutics Inc (NASDAQ: SMMT) said it would seek partners or divestiture of ridinilazole as the path forward for the clinical development of the asset.